المؤلفون: Blanca Olivia Murillo-Ortiz, Kenia García-Corrales, Sandra Martínez-Garza, Marcos Javier Romero-Vázquez, Eduardo Agustín-Godínez, Andrea Escareño-Gómez, Daniela Guadalupe Silva-Guerrero, Saulo Mendoza-Ramírez, Mario Murguia-Perez

المصدر: Frontiers in Medicine, Vol 11 (2024)

مصطلحات موضوعية: hTERT, telomere, telomerase, Her2-neu, immunohistochemistry, Medicine (General), R5-920

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fmed.2024.1450147/full; https://doaj.org/toc/2296-858X

URL الوصول: https://doaj.org/article/5014350fe97e453399e0ae949a5fef3e

المؤلفون: I. V. Mikhailov, E. R. Eremeeva, A. A. Glazkov, I. M. Telezhnikova, G. R. Setdikova, A. S. Balkanov, И. В. Михайлов, Е. Р. Еремеева, А. А. Глазков, И. М. Тележникова, Г. Р. Сетдикова, А. С. Балканов

المصدر: Siberian journal of oncology; Том 23, № 5 (2024); 47-58 ; Сибирский онкологический журнал; Том 23, № 5 (2024); 47-58 ; 2312-3168 ; 1814-4861

مصطلحات موضوعية: периневральная инвазия, negative HER2-neu status, HER2-low status, tumor-associated macrophages, perineural invasion, негативный HER2-neu статус, HER2-low статус, опухоль-ассоциированные макрофаги

وصف الملف: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/3266/1270; Pernas S., Tolaney S.M. Clinical trial data and emerging strategies: HER2-positive breast cancer. Breast Cancer Res Treat. 2022; 193(2): 281–91. doi:10.1007/s10549-022-06575-7.; Denkert C., Seither F., Schneeweiss A., Link T., Blohmer J.U., Just M., Wimberger P., Forberger A., Tesch H., Jackisch C., Schmatloch S., Reinisch M., Solomayer E.F., Schmitt W.D., Hanusch C., Fasching P.A., Lübbe K., Solbach C., Huober J., Rhiem K., Marmé F., Reimer T., Schmidt M., Sinn B.V., Janni W., Stickeler E., Michel L., Stötzer O., Hahnen E., Furlanetto J., Seiler S., Nekljudova V., Untch M., Loibl S. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021; 22(8): 1151–61. doi:10.1016/S1470-2045(21)00301-6.; Jin J., Li B., Cao J., Li T., Zhang J., Cao J., Zhao M., Wang L., Wang B., Tao Z., Hu X. Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer. J Transl Med. 2023; 21(1): 360. doi:10.1186/s12967-023-04076-9.; Вторушин С.В., Крахмаль Н.В., Завалишина Л.Э., Кузнецова О.А., Москвина Л.В., Франк Г.А. Определение HER2-статуса карцином различных локализаций. Архив патологии. 2023; 85(6): 31–46. doi:10.17116/patol20238506131.; Schlam I., Tolaney S.M., Tarantino P. How I treat HER2-low advanced breast cancer. Breast. 2023; 67: 116–23. doi:10.1016/j.breast.2023.01.005.; Moy B., Wolff A.C., Rumble R.B., Allison K.H., Carey L.A. Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer and Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. JCO Oncol Pract. 2023; 19(8): 547–50. doi:10.1200/OP.23.00047.; Vaziri Fard E., Ali Y., Wang X.I., Saluja K., H Covinsky M., Wang L., Zhang S. Tumor-Infltrating Lymphocyte Volume Is a Better Predictor of Disease-Free Survival Than Stromal Tumor-Infltrating Lymphocytes in Invasive Breast Carcinoma. Am J Clin Pathol. 2019; 152(5): 656–65. doi:10.1093/ajcp/aqz088.; García-Martínez E., Gil G.L., Benito A.C., González-Billalabeitia E., Conesa M.A., García García T., García-Garre E., Vicente V., Ayala de la Peña F. Tumor-infltrating immune cell profles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res. 2014; 16(6): 488. doi:10.1186/s13058-014-0488-5.; Skriver S.K., Jensen M.B., Knoop A.S., Ejlertsen B., Laenkholm A.V. Tumour-infltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial. Breast Cancer Res. 2020; 22(1): 46. doi:10.1186/s13058-020-01285-8.; Salgado R., Denkert C., Campbell C., Savas P., Nuciforo P., Aura C., de Azambuja E., Eidtmann H., Ellis C.E., Baselga J., PiccartGebhart M.J., Michiels S., Bradbury I., Sotiriou C., Loi S. TumorInfltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. JAMA Oncol. 2015; 1(4): 448–54. doi:10.1001/jamaoncol.2015.0830. Erratum in: JAMA Oncol. 2015; 1(4): 544. doi:10.1001/jamaoncol.2015.1805. Erratum in: JAMA Oncol. 2015; 1(8): 1172. doi:10.1001/jamaoncol.2015.4229. Nucifero, Paolo [corrected to Nuciforo, Paolo]. Erratum in: JAMA Oncol. 2019; 5(1): 122. doi:10.1001/jamaoncol.2018.5678.; Perez E.A., Ballman K.V., Tenner K.S., Thompson E.A., Badve S.S., Bailey H., Baehner F.L. Association of Stromal Tumor-Infltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. JAMA Oncol. 2016; 2(1): 56–64. doi:10.1001/jamaoncol.2015.3239.; Fernandez-Martinez A., Pascual T., Singh B., Nuciforo P., Rashid N.U., Ballman K.V., Campbell J.D., Hoadley K.A., Spears P.A., Pare L., Brasó-Maristany F., Chic N., Krop I., Partridge A., Cortés J., Llombart-Cussac A., Prat A., Perou C.M., Carey L.A. Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs TumorInfltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials. JAMA Oncol. 2023; 9(4): 490–9. doi:10.1001/jamaoncol.2022.6288.; Pruneri G., Gray K.P., Vingiani A., Viale G., Curigliano G., Criscitiello C., Láng I., Ruhstaller T., Gianni L., Goldhirsch A., Kammler R., Price K.N., Cancello G., Munzone E., Gelber R.D., Regan M.M., Colleoni M. Tumor-infltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. Breast Cancer Res Treat. 2016; 158(2): 323–31. doi:10.1007/s10549-016-3863-3.; Киселевский М.В., Власенко Р.Я., Заботина Т.Н., Кадагидзе З.Г. Прогностическая значимость опухоль-инфильтрирующих лимфоцитов. Иммунология. 2019; 40(1): 73–82. doi:10.24411/0206-4952-2019-11009.; Lundgren C., Bendahl P.O., Ekholm M., Fernö M., Forsare C., Krüger U., Nordenskjöld B., Stål O., Rydén L. Tumour-infltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up. Breast Cancer Res. 2020; 22(1): 140. doi:10.1186/s13058-020-01364-w.; Gwak J.M., Jang M.H., Kim D.I., Seo A.N., Park S.Y. Prognostic value of tumor-associated macrophages according to histologic locations and hormone receptor status in breast cancer. PLoS One. 2015; 10(4). doi:10.1371/journal.pone.0125728.; Mehraj U., Qayoom H., Mir M.A. Prognostic signifcance and targeting tumor-associated macrophages in cancer: new insights and future perspectives. Breast Cancer. 2021; 28(3): 539–55. doi:10.1007/s12282-021-01231-2.; Hendry S., Salgado R., Gevaert T. et al. Assessing Tumor-infltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Adv Anat Pathol. 2017; 24(5): 235–51. doi:10.1097/PAP.0000000000000162.; Wei C., Yang C., Wang S., Shi D., Zhang C., Lin X., Liu Q., Dou R., Xiong B. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol Cancer. 2019; 18(1): 64. doi:10.1186/s12943-019-0976-4.; Anderson S., Bartow B.B., Siegal G.P., Huang X., Wei S. The dynamics of HER2-low expression during breast cancer progression. Breast Cancer Res Treat. 2023; 201(3): 437–46. doi:10.1007/s10549-023-07020-z.; van den Ende N.S., Nguyen A.H., Jager A., Kok M., Debets R., van Deurzen C.H.M. Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review. Int J Mol Sci. 2023; 24(3): 2969. doi:10.3390/ijms24032969.; Takada K., Kashiwagi S., Asano Y., Goto W., Kouhashi R., Yabumoto A., Morisaki T., Shibutani M., Takashima T., Fujita H., Hirakawa K., Ohira M. Prediction of lymph node metastasis by tumor-infltrating lymphocytes in T1 breast cancer. BMC Cancer. 2020; 20(1): 598. doi:10.1186/s12885-020-07101-y.; Jeong H., Hwang I., Kang S.H., Shin H.C., Kwon S.Y. TumorAssociated Macrophages as Potential Prognostic Biomarkers of Invasive Breast Cancer. J Breast Cancer. 2019; 22(1): 38–51. doi:10.4048/ jbc.2019.22.e5.; Kashyap D., Bal A., Irinike S., Khare S., Bhattacharya S., Das A., Singh G. Heterogeneity of the Tumor Microenvironment Across Molecular Subtypes of Breast Cancer. Appl Immunohistochem Mol Morphol. 2023; 31(8): 533–43. doi:10.1097/PAI.0000000000001139.; Allison E., Edirimanne S., Matthews J., Fuller S.J. Breast Cancer Survival Outcomes and Tumor-Associated Macrophage Markers: A Systematic Review and Meta-Analysis. Oncol Ther. 2023; 11(1): 27–48. doi:10.1007/s40487-022-00214-3.; Zhao X., Qu J., Sun Y., Wang J., Liu X., Wang F., Zhang H., Wang W., Ma X., Gao X., Zhang S. Prognostic signifcance of tumor-associated macrophages in breast cancer: a meta-analysis of the literature. Oncotarget. 2017; 8(18): 30576–86. doi:10.18632/oncotarget.15736.; Muraro E., Martorelli D., Turchet E., Miolo G., Scalone S., Comaro E., Talamini R., Mastorci K., Lombardi D., Perin T., Carbone A., Veronesi A., Crivellari D., Dolcetti R. A diferent immunologic profle characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies. Breast Cancer Res. 2011; 13(6). doi:10.1186/bcr3060.; Mohamed R.F., Abdelhameed D.H., Mohamed M.A. Combination of Anatomical and Biological Factors to Predict Disease-Free Survival in Breast Cancer. JCO Glob Oncol. 2023; 9. doi:10.1200/GO.22.00269.; Wang X., Zhang L., Zhang X., Luo J., Wang X., Chen X., Yang Z., Mei X., Yu X., Zhang Z., Guo X., Shao Z., Ma J. Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy? Breast Cancer Res Treat. 2021; 190(2): 277–86. doi:10.1007/s10549-021-06378-2.; Mittendorf E.A., Ballman K.V., McCall L.M., Yi M., Sahin A.A., Bedrosian I., Hansen N., Gabram S., Hurd T., Giuliano A.E., Hunt K.K. Evaluation of the stage IB designation of the American Joint Committee on Cancer staging system in breast cancer. J Clin Oncol. 2015; 33(10): 1119–27. doi:10.1200/JCO.2014.57.2958.; https://www.siboncoj.ru/jour/article/view/3266

الاتاحة: https://www.siboncoj.ru/jour/article/view/3266
https://doi.org/10.21294/1814-4861-2024-23-5-47-58

المؤلفون: A. L. Kornietskaya, S. F. Evdokimova, L. V. Bolotina, A. A. Fedenko, А. Л. Корниецкая, С. Ф. Евдокимова, Л. В. Болотина, А. А. Феденко

المصدر: Meditsinskiy sovet = Medical Council; № 10 (2024); 145-150 ; Медицинский Совет; № 10 (2024); 145-150 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: клинический случай, esophagogastric junction cancer, trastuzumab deruxtecan, chemotherapy, HER2-neu, trastuzumab resistance, case report, кардиоэзофагеальный переход, трастузумаб дерукстекан, химиотерапия, резистентность к трастузумабу

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8406/7397; Каприн АД (ред.). Злокачественные новообразования в России в 2022 году. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2023. Режим доступа: https://oms66.ru/upload/iblock/52d/6u9uo6ajmjooxfl8m738lck2qzog7lza/zno_2022.pdf.; Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. https://doi.org/10.3322/caac.21660.; Hofmann M, Stoss O, Shi D, Büttner R, Van De Vijver M, Kim W et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797–805. https://doi.org/10.1111/j.1365-2559.2008.03028.x.; Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer THERapy. Chem Pharm Bull (Tokyo). 2019;67:173–185. https://doi.org/10.1248/cpb.c18-00744.; Gao X, Zhao L, Zhang N, Han W, Liu K, Yan J et al. Impact of HER2 on prognosis and benefit from adjuvant chemotHERapy in stage II/III gastric cancer patients: a multicenter observational study. Int J Surg Lond Engl. 2023;109:1330–1341. https://doi.org/10.1097/JS9.0000000000000370.; Motoshima S, Yonemoto K, Kamei H, Morita M, Yamaguchi R. Prognostic implications of HER2 heterogeneity in gastric cancer. Oncotarget. 2018;9(10):9262–9272. https://doi.org/10.18632/oncotarget.24265.; Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al. Trastuzumab in combination with chemotHERapy versus chemotHERapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet. 2010;376:687–697. https://doi.org/10.1016/S0140-6736(10)61121-X.; Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18(5):640–653. https://doi.org/10.1016/S1470-2045(17)30111-0.; Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K et al. Pertuzumab plus trastuzumab and chemotHERapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a doubleblind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19:1372–1384. https://doi.org/10.1016/S1470-2045(18)30481-9.; Satoh T, Xu R-H, Chung HC, Sun G-P, Doi T, Xu J-M et al. Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2Amplified Advanced Gastric Cancer in Asian Populations: TyTAN – A Randomized, Phase III Study. J Clin Oncol. 2014;32(19):2039–2049. https://doi.org/10.1200/JCO.2013.53.6136.; Hecht JR, Bang Y-J, Qin SK, Chung HC, Xu JM, Park JO et al. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial. J Clin Oncol. 2016;34:443–451. https://doi.org/10.1200/JCO.2015.62.6598.; Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med. 2012;367(19):1783–1791. https://doi.org/10.1056/NEJMoa1209124.; Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387(1):9–20. https://doi.org/10.1056/NEJMoa2203690.; Hurvitz SA, Hegg R, Chung W-P, Im S-A, Jacot W, Ganju V et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. The Lancet. 2023;401(10371):105–117. https://doi.org/10.1016/S0140-6736(22)02420-5.; Shitara K, Bang Y-J, Iwasa S, Sugimoto N, Ryu M-H, Sakai D et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020;382(25):2419–2430. https://doi.org/10.1056/NEJMoa2004413.; Le DT, Ott PA, Korytowsky B, Le H, Le TK, Zhang Y et al. Real-world Treatment Patterns and Clinical Outcomes Across Lines of THERapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. Clin Colorectal Cancer. 2020;19(1):32-38.e3. https://doi.org/10.1016/j.clcc.2019.09.001.; Seo S, Ryu M-H, Park YS, Ahn JY, Park Y, Park SR et al. Loss of HER2 positivity after anti-HER2 chemotHERapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). Gastric Cancer. 2019;22(3):527–535. https://doi.org/10.1007/s10120-018-0891-1.; https://www.med-sovet.pro/jour/article/view/8406

الاتاحة: https://www.med-sovet.pro/jour/article/view/8406
https://doi.org/10.21518/ms2024-250

المؤلفون: Joseph Kattan, Fady el Karak, Fadi Farhat, Dany Abi Gerges, Walid Mokaddem, Georges Chahine, Saad Khairallah, Najla Fakhruddin, Jawad Makarem, Fadi Nasr

المصدر: BMC Cancer, Vol 22, Iss 1, Pp 1-8 (2022)

مصطلحات موضوعية: Gastric cancer, HER2-neu, Immunohistochemistry (IHC), In-situ hybridization (ISH), Prevalence, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://doaj.org/toc/1471-2407

URL الوصول: https://doaj.org/article/746c8036181b4ccc842f195c32a5ce67

المؤلفون: Mahmoud Reza Kalantari, Reza Mahdavi Zafarghandi, Mahmoud Tavakkoli, Shakiba Kalantari, Atena Aghaee, Amin Mirsani, Salman Soltani

المصدر: Patient Safety and Quality Improvement Journal, Vol 7, Iss 2, Pp 69-74 (2019)

مصطلحات موضوعية: Prostate cancer, HER2-neu peptide, imaging guided biopsies, Gleason score, Medicine (General), R5-920

وصف الملف: electronic resource

Relation: http://psj.mums.ac.ir/article_12905_b815edbeaeab624cf90566f9edf82351.pdf; https://doaj.org/toc/2345-4482; https://doaj.org/toc/2345-4490

URL الوصول: https://doaj.org/article/71ae6b54165146afbd6571f0e68aa0dc

المؤلفون: Sanjeev Narang, Parul Dargar, Anjali Singh, Apurva Malhotra

المصدر: Journal of Pathology of Nepal, Vol 8, Iss 1, Pp 1297-1300 (2018)

مصطلحات موضوعية: Breast, Cancer, GATA-3, HER2-Neu, pAKT, Triple negative, Pathology, RB1-214

وصف الملف: electronic resource

Relation: https://www.nepjol.info/index.php/JPN/article/view/19457; https://doaj.org/toc/2091-0797; https://doaj.org/toc/2091-0908

URL الوصول: https://doaj.org/article/e503fb25c59540689f43add2b3377622

المؤلفون: Asif Ali , Mushtaq Ahmad , Nabila Javeed , Muhammad Ijaz , Mah Muneer Khan , Rauf Khattak , Mazhar Khan , Syeda Afsheen Hasnain Daud , Asma Fayyaz , Muhammad Naseem Khan , Abdul Salam , Zoufishan Rahat , Maham Israr

المصدر: Journal of Islamic International Medical College, Vol 12, Iss 4, Pp 208-212 (2017)

مصطلحات موضوعية: breast cancer, clinico-pathologic, estrogen receptors, her2-neu peptide, lymph nodes, progesterone receptor., Medicine

وصف الملف: electronic resource

Relation: https://journals.riphah.edu.pk/index.php/jiimc/article/view/1013; https://doaj.org/toc/1815-4018; https://doaj.org/toc/2410-5422

URL الوصول: https://doaj.org/article/cdb4e15425744466844ef484a77ea440

المؤلفون: Gopi Aryal, Sameer Chhetri Aryal, Yurie Soejima, Victoria Sheckler, Yoshinobu Eishi, Motoji Sawabe

المصدر: Journal of Pathology of Nepal, Vol 7, Iss 2, Pp 1196-1201 (2017)

مصطلحات موضوعية: Breast, Cancer, GATA-3, HER2-Neu, pAKT, Triple negative, Pathology, RB1-214

وصف الملف: electronic resource

Relation: http://www.nepjol.info/index.php/JPN/article/view/18037; https://doaj.org/toc/2091-0797; https://doaj.org/toc/2091-0908

URL الوصول: https://doaj.org/article/9dc17d0094504dcc8fd6ee1d5a0c8d3a

المؤلفون: Banerjee, Sanatan, Das, Diptimay, Bhattacharya, Biswamit, Chaudhury, Arindam

المصدر: International Journal of Research in Medical Sciences; Vol. 8 No. 12 (2020): December 2020; 4395-4399 ; 2320-6012 ; 2320-6071

مصطلحات موضوعية: HER2-neu, Ki67, Hormone receptor positivity, Premenopausal

وصف الملف: application/pdf

Relation: https://www.msjonline.org/index.php/ijrms/article/view/8914/6173; https://www.msjonline.org/index.php/ijrms/article/view/8914

الاتاحة: https://www.msjonline.org/index.php/ijrms/article/view/8914
https://doi.org/10.18203/2320-6012.ijrms20205312

المؤلفون: Ayesha Ahmed, Dalal M. Al-Tamimi

المصدر: Libyan Journal of Medicine, Vol 13, Iss 1 (2018)

مصطلحات موضوعية: p-53, Ki-67, Her2-neu, gastric adenocarcinoma, Medicine

وصف الملف: electronic resource

Relation: https://doaj.org/toc/1993-2820; https://doaj.org/toc/1819-6357

URL الوصول: https://doaj.org/article/93e74a59d1894b9db9d8b9d50e9e5839

المؤلفون: Gowry Maram Reddy, Pooja K. Suresh, Radha R. Pai

المصدر: Journal of Clinical and Diagnostic Research, Vol 11, Iss 1, Pp EC05-EC08 (2017)

مصطلحات موضوعية: aggressive behaviour, estrogen receptor, her2-neu, progesterone receptor, Medicine

وصف الملف: electronic resource

Relation: https://jcdr.net/articles/PDF/9187/21452_CE(RA1)_F(T)_PF1(GU_SRI)_PFA(AK)_PF2(PK_RK).pdf; https://doaj.org/toc/2249-782X; https://doaj.org/toc/0973-709X

URL الوصول: https://doaj.org/article/57c883e63a3347c7982ddece429a6e0d

المصدر: Journal of Islamic International Medical College, Vol 12, Iss 4, Pp 208-212 (2017)

مصطلحات موضوعية: breast cancer, clinico-pathologic, estrogen receptors, her2-neu peptide, lymph nodes, progesterone receptor, Medicine

Relation: https://journals.riphah.edu.pk/index.php/jiimc/article/view/1013; https://doaj.org/toc/1815-4018; https://doaj.org/toc/2410-5422; https://doaj.org/article/cdb4e15425744466844ef484a77ea440

الاتاحة: https://doaj.org/article/cdb4e15425744466844ef484a77ea440

المؤلفون: Megha Joshi, Sriharshan J Reddy, Manjiri Nanavidekar, John P Russo, Armand V Russo, Ram Pathak

المصدر: Indian Journal of Pathology and Microbiology, Vol 54, Iss 4, Pp 671-682 (2011)

مصطلحات موضوعية: Breast, biopsy, breast cancer, carcinoma, ductal carcinoma in situ, ER, fibroepithelial lesions, Her2-neu, PR, phyllodes tumor, Pathology, RB1-214, Microbiology, QR1-502

وصف الملف: electronic resource

Relation: http://www.ijpmonline.org/article.asp?issn=0377-4929;year=2011;volume=54;issue=4;spage=671;epage=682;aulast=Joshi; https://doaj.org/toc/0377-4929

URL الوصول: https://doaj.org/article/164d6c9bc7ab41058a28ff7d35dd51c3

المؤلفون: Öven Ustaalioğlu, Bala Başak, Aker Vardar, Fügen, Bilici, Ahmet, Gürleyik, Günay, Erkol, Burçak, Kefeli, Umut, Aliustaoglu, Mehmet

مصطلحات موضوعية: Breast Cancer, Discordance, HER2-Neu, Hormone Receptor, Neoadjuvant Chemotherapy

وصف الملف: application/pdf

Relation: Journal of the Balkan Union of Oncology; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; Öven Ustaalioğlu, B. B., Aker Vardar, F., Bilici, A., Gürleyik, G., Erkol, B., Kefeli, U. . Aliustaoglu, M. (2014). Clinical importance of discordance of hormone receptors and Her2/neu status after neoadjuvant chemotherapy in breast cancer. Journal of the Balkan Union of Oncology, 19(4). 879-886.; https://hdl.handle.net/20.500.12511/2989; 19; 879; 886; Q4; Q3

الاتاحة: https://hdl.handle.net/20.500.12511/2989

المؤلفون: Kara O., Duman B.B., Kara B., Erdogan S., Parsak C.K., Sakman G.

المساهمون: Çukurova Üniversitesi

مصطلحات موضوعية: Bevacizumab, Colorectal cancer, HER2-neu, p53, PTEN, VEGF

Relation: Asian Pacific Journal of Cancer Prevention; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://dx.doi.org/10.7314/APJCP.2012.13.12.6397; https://hdl.handle.net/20.500.12605/11010; 13; 12; 6397; 6401

الاتاحة: https://hdl.handle.net/20.500.12605/11010
https://doi.org/10.7314/APJCP.2012.13.12.6397

المؤلفون: Anjali Singh, Sanjeev Narang, Parul Dargar, Apurva Malhotra

المصدر: Journal of Pathology of Nepal, Vol 8, Iss 1, Pp 1297-1300 (2018)

مصطلحات موضوعية: HER2-Neu, medicine.medical_specialty, Pap smears, medicine.diagnostic_test, business.industry, pAKT, Retrospective cohort study, medicine.disease, Malignancy, GATA-3, Predictive value, Gastroenterology, Atypical Glandular Cell, Internal medicine, Cytology, Biopsy, medicine, lcsh:Pathology, Adenocarcinoma, Breast, business, Triple negative, Cancer, lcsh:RB1-214

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::932bdc3479aed1b67eea71224e9b9cad
https://www.nepjol.info/index.php/JPN/article/view/19457

المؤلفون: Benítez, J. S., Alfaro, N., Insfrán, Rosa María, Merlo, Winnie Amalia, Rosciani, Adriana Silvia

المصدر: Revista Veterinaria, 2011, vol. 22, no. 2, p. 119-122.

مصطلحات موضوعية: Perro, Neoplasia mamaria, Receptores ERα/Her2-neu, Valor pronóstico, Bitch, Mammary neoplasia, Receptors ERα / Her2-neu, Prognostic value

وصف الملف: application/pdf; p. 119-122

Relation: https://revistas.unne.edu.ar/index.php/vet/article/view/1834; http://dx.doi.org/10.30972/vet.2221834; Benítez, J. S., et al., 2011. Eficacia pronóstica de la determinación de los receptoresmoleculares ERα y Her2-neu en tumores mamarios caninos. Revista Veterinaria. Corrientes: Universidad Nacional del Nordeste. Facultad de Ciencias Veterinarias, vol. 22, no. 2, p. 119-122. ISSN 1669-6840. http://dx.doi.org/10.30972/vet.2221834; http://repositorio.unne.edu.ar/handle/123456789/48960

الاتاحة: http://repositorio.unne.edu.ar/handle/123456789/48960

المؤلفون: Kolomiiets, Olena Olehivna, Yazykov, Oleksandr Valeriiovych, Lukavenko, Ivan Mykhailovych, Andriushchenko, Volodymyr Viktorovych, Romaniuk, Anatolii Mykolaiovych, Moskalenko, Roman Andriiovych

مصطلحات موضوعية: HER2-neu, breast cancer, gene expression, skin and connective tissue diseases, microcalcifications

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od______2001::d2c54548ffc0a7ad4b2ea68e1d14681f
https://essuir.sumdu.edu.ua/handle/123456789/81351

المؤلفون: Khanal, Suman, Singh, Yogendra P, Shrivastav, Shreya

المصدر: Journal of Institute of Medicine Nepal; Vol. 41 No. 3 (2019); 89-91 ; 1993-2987 ; 1993-2979

مصطلحات موضوعية: Breast cancer, chemotherapy, HER2-neu, pregnancy

وصف الملف: application/pdf

Relation: https://nepjol.info/index.php/JIOM/article/view/37377/28938; https://nepjol.info/index.php/JIOM/article/view/37377

الاتاحة: https://nepjol.info/index.php/JIOM/article/view/37377

المؤلفون: Alaa A El-Sisi, Manal A Safan

المصدر: Egyptian Journal of Biochemistry and Molecular Biology; Vol 34, No 1-2 (2016); 39-50

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Population, HER2/neu, Metastasis, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Internal medicine, Genotype, medicine, TNRC9 gene, Her2-neu, real time PCR, breast cancer, Allele, skin and connective tissue diseases, education, Gynecology, education.field_of_study, biology, business.industry, medicine.disease, Genotype frequency, 030220 oncology & carcinogenesis, biology.protein, 030211 gastroenterology & hepatology, business, Breast feeding

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd4f0efdf2ac6cb1d2789a15653a6b44
https://doi.org/10.21608/ejb.2016.9649